SRPT

Company Overview — What Does Sarepta Therapeutics, Inc. Do?

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Sarepta Therapeutics, Inc. (SRPT) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Douglas S. Ingram and employs approximately 840 people, headquartered in CAMBRIDGE, Massachusetts. With a market capitalization of $2.3B, SRPT is one of the notable companies in the Healthcare sector.

Sarepta Therapeutics, Inc. (SRPT) Stock Rating — Reduce (April 2026)

As of April 2026, Sarepta Therapeutics, Inc. receives a Reduce rating with a composite score of 29.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SRPT ranks #2,926 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Sarepta Therapeutics, Inc. ranks #415 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SRPT Stock Price and 52-Week Range

Sarepta Therapeutics, Inc. (SRPT) currently trades at $21.32. The stock lost $0.91 (4.1%) in the most recent trading session. The 52-week high for SRPT is $80.26, which means the stock is currently trading -73.4% from its annual peak. The 52-week low is $10.41, putting the stock 104.7% above its annual trough. Recent trading volume was 2.0M shares, reflecting moderate market activity.

Is SRPT Overvalued or Undervalued? — Valuation Analysis

Sarepta Therapeutics, Inc. (SRPT) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.12x, versus the sector average of 2.75x. The price-to-sales ratio is 1.09x, compared to 1.66x for the average Healthcare stock.

At current multiples, Sarepta Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Sarepta Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Sarepta Therapeutics, Inc. (SRPT) earns a quality factor score of 35/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -23.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -8.0% versus the sector average of -33.1%.

On a margin basis, Sarepta Therapeutics, Inc. reports gross margins of 59.2%, compared to 71.5% for the sector. The operating margin is -10.6% (sector: -66.1%). Net profit margin stands at -8.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 10.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SRPT Debt, Balance Sheet, and Financial Health

Sarepta Therapeutics, Inc. has a debt-to-equity ratio of 73.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $829M. Cash and equivalents stand at $613M.

SRPT has a beta of 1.77, meaning it is more volatile than the broader market — a $10,000 investment in SRPT would be expected to move 77.0% more than the S&P 500 on any given day. The stability factor score for Sarepta Therapeutics, Inc. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Sarepta Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Sarepta Therapeutics, Inc. reported revenue of $2.22B and earnings per share (EPS) of $-7.13. Net income for the quarter was $-268M. Gross margin was 59.2%. Operating income came in at $-266M.

In FY 2025, Sarepta Therapeutics, Inc. reported revenue of $2.20B and earnings per share (EPS) of $-7.13. Net income for the quarter was $-713M. Gross margin was 98.8%. Revenue grew 15.6% year-over-year compared to FY 2024. Operating income came in at $-700M.

In Q3 2025, Sarepta Therapeutics, Inc. reported revenue of $399M and earnings per share (EPS) of $-0.50. Net income for the quarter was $-51M. Gross margin was 54.9%. Revenue grew -14.5% year-over-year compared to Q3 2024. Operating income came in at $-103M.

In Q2 2025, Sarepta Therapeutics, Inc. reported revenue of $611M and earnings per share (EPS) of $2.01. Net income for the quarter was $197M. Gross margin was 59.0%. Revenue grew 68.4% year-over-year compared to Q2 2024. Operating income came in at $116M.

Over the past 8 quarters, Sarepta Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $363M to $2.22B. Investors analyzing SRPT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SRPT Dividend Yield and Income Analysis

Sarepta Therapeutics, Inc. (SRPT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SRPT Momentum and Technical Analysis Profile

Sarepta Therapeutics, Inc. (SRPT) has a momentum factor score of 30/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 44/100 reflects moderate short selling activity.

SRPT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Sarepta Therapeutics, Inc. (SRPT) ranks #415 out of 838 stocks based on the Blank Capital composite score. This places SRPT in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SRPT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SRPT vs S&P 500 (SPY) comparison to assess how Sarepta Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

SRPT Next Earnings Date

No upcoming earnings date has been announced for Sarepta Therapeutics, Inc. (SRPT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SRPT? — Investment Thesis Summary

The quantitative profile for Sarepta Therapeutics, Inc. suggests caution. The quality score of 35/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. Momentum is weak at 30/100, a headwind for near-term performance. High volatility (stability score 13/100) increases portfolio risk.

In summary, Sarepta Therapeutics, Inc. (SRPT) earns a Reduce rating with a composite score of 29.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SRPT stock.

Related Resources for SRPT Investors

Explore more research and tools: SRPT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SRPT head-to-head with peers: SRPT vs AZN, SRPT vs SLGL, SRPT vs VMD.